Columbia University
1212 Amsterdam Avenue
500 Fairchild
New York
NY
10027
United States
Tel: 2128545016
Website: https://www.columbia.edu/
17 articles with Columbia University
-
Actinium Pharmaceuticals, Inc. Announces Research Collaboration with Columbia University to Study Actimab-A in AML Patients Following Transplant of Engineered Hematopoietic Stem Cells Gene Edited to be CD33 Negative
12/8/2022
Actinium Pharmaceuticals, Inc. today announced that it has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells (eHSCs) modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression.
-
Researchers have discovered a potential treatment target for Down syndrome, Th17 cells could mitigate microbiome-linked diseases and electroacupuncture in Parkinson's disease.
-
The 3D-printed acoustic hologram could be very important to the delivery of certain therapeutics for Alzheimer’s Disease (AD) and other neurological disorders.
-
A new discovery related to the mechanism of the danger signal adenosine triphosphate could influence how immunomodulators, such as vaccines and allergy medications, are formulated.
-
BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal
8/1/2022
BioXcel Therapeutics, Inc. today announced that the National Institute on Drug Abuse, part of the National Institutes of Health (NIH), has awarded Columbia University a multi-year NIDA grant to fund clinical testing of BXCL501 (sublingual dexmedetomidine) as a potential treatment for opioid withdrawal.
-
New research by investigators at Columbia University and MIT describes how cancer cells often depend upon the importation of fat for continued growth and division.
-
The initiative, a partnership between non-profit biotech company n-Lorem and Columbia University, focuses on developing personalized experimental ASO medicines for nano-rare ALS patients.
-
Pfizer apparently hasn't begun any combination trials in human beings of Paxlovid, and no reported human tests are using the drug in combination with other therapies.
-
In honor of ALS Awareness Month, BioSpace spoke with leading researchers like Dr. Matthew Harms of Columbia University and Drs. Howard Berman and Stanley Appel at Coya Therapeutics.
-
n-Lorem Foundation and Columbia University Establish Silence ALS Initiative
5/3/2022
n-Lorem announced today the formation of Silence ALS, an initiative that aligns Columbia University and n-Lorem in support of the characterization of nano-rare amyotrophic lateral sclerosis (ALS) patients.
-
The FDA has stated that GSK and Vir’s COVID-19 treatment sotrovimab is no longer authorized to be used for the condition because of its low efficacy against Omicron sub-variant BA.2.
-
Researchers have developed a new form of UV light that is safe for people but decreased the level of indoor airborne microbes by more than 98% in less than five minutes.
-
Researchers may have found a potential treatment for congenital heart defects in a surprising source: an over-the-counter cough suppressant. Know more here.
-
High Performing Algorithm To Translate Paralyzed Patients' Thoughts Into Real-Time Prosthetic Movements
2/8/2022
Blackrock Neurotech, the leader in brain-computer interface technology, has signed an exclusive license for Columbia University's neural decoder MINT.
-
Over the past ten years, Tonix's pipeline has evolved to also comprise assets in biodefense, immunology and cancer therapeutics.
-
BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers
10/29/2021
- The new agreements mean BridgeBio has collaborations with 25 leading academic institutions focused on genetic disease and precision oncology
-
Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease Agreement Provides for Option to License Alzheimer’s Therapeutic
10/27/2021
Silo Pharma, Inc. today announced that it has entered into a sponsored research agreement with Columbia University pursuant to which Silo has been granted an option to license certain assets currently under development, including Alzheimer’s disease.